InMed Pharmaceuticals Inc. (NasdaqCM: INM)
Health Care · Pharmaceuticals · CA
$1.38
+1.47% today · -35.9% 1Y
InMed Pharmaceuticals Inc. (NasdaqCM: INM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $9.04M and employs 6 people.
Over the last twelve months the share price has lost 35.9%, trading between 0.58 and 2.40.
Tweenvest scores InMed Pharmaceuticals Inc. across four factors: quality 35/100, value 87/100. Its strongest factor is value.
INM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.04M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.12
- Dividend yield
- —
- Beta (5Y)
- 0.93
- 52-week high
- $2.40
- 52-week low
- $0.58
- Avg volume (3M)
- —
- Shares outstanding
- 6.64M
- Employees
- 6
- Next earnings
- —
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
- ISIN
- CA4576377002
- Founded
- 1981
- Listed since
- May 5, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Active Fine Chemicals LimitedDSE: ACTIVEFINE | $9.55M | Tk4.90 | -10.91% |
| Mercury Laboratories LimitedBSE: 538964 | $9.54M | Rs770.00 | +2.94% |
| S.C. Sintofarm S.A.BVB: SINT | $9.37M | RON— | — |
| Marinomed Biotech AGWBAG: MARI | $9.11M | €— | — |
| PEPTONIC medical AB (publ)XSAT: PMED | $8.90M | Skr0.00 | — |
| Amwill Health Care LimitedBSE: 544353 | $8.89M | Rs43.00 | +1.18% |
| Vitura Health LimitedASX: VIT | $8.79M | AU$0.02 | -5.00% |
| Mediplantex National Pharmaceutical Joint Stock CompanyHNX: MED | $8.68M | ₫— | — |
Figures last refreshed Oct 11, 2026.